Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (IQV) delivers integrated healthcare insights through its unique combination of clinical research expertise and advanced data analytics. This news hub provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access official press releases and curated news coverage spanning clinical trial milestones, healthcare data partnerships, regulatory updates, and technology innovations. Our collection serves as a strategic resource for understanding IQVIA's role in optimizing drug development cycles and commercial decision-making.
Key content categories include earnings announcements, merger/acquisition activity, leadership changes, and analytical breakthroughs in real-world evidence applications. Bookmark this page for efficient tracking of IQVIA's progress in transforming clinical research through data-driven solutions.
The IQVIA Institute has released a report detailing the global rise in cancer diagnoses and the corresponding increase in innovative cancer therapies. Cancer incidence is projected to reach 32 million new cases annually by 2050, especially in lower-income countries.
Global spending on cancer medicines rose to $223 billion in 2023 and is expected to hit $409 billion by 2028. The year 2023 saw the launch of 25 novel active substances (NASs) in oncology, bringing the total to 193 since 2014.
Over 2,000 new oncology clinical trials began in 2023, featuring advanced therapies like cell and gene therapies, antibody-drug conjugates, and radioligand therapies. Despite advancements, geographic disparities in access to these therapies persist.
Oncology trials have become less complex, increasing the success rate to 10% in 2023 from 4% the previous year. However, the pace of bringing new therapies to patients remains uneven due to differences in healthcare infrastructure and adoption rates.
Overall spending on medicines in the U.S. grew by 2.5% in 2023, reaching $435 billion. Excluding COVID-19 vaccines and therapeutics, the growth rate was 9.9%, driven by advances in oncology, immunology, diabetes, and obesity treatments. Patient out-of-pocket costs rose to $91 billion, influenced by wider use of GLP-1 agonists for diabetes and obesity. New prescriptions increased by 4%, while patient visits and diagnostics fell by 4-6%. The flu vaccination rate dropped by 17%. The IQVIA Health Services Utilization Index fell 3% to 97. The report projects continued growth in medicine spending, driven by innovation but tempered by patent expirations and the introduction of biosimilars. Net pharmaceutical spending is forecasted to grow at 4-7% annually through 2028, with oncology and obesity as primary growth drivers.
IQVIA Holdings Inc. announced that Ron Bruehlman, CFO, will speak at the Bank of America Health Care Conference on May 14, 2024. The presentation will be webcasted live and available for replay on the IQVIA Investor Relations website.
IQVIA Holdings Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $3,737 million, GAAP Net Income of $288 million, and Adjusted EBITDA of $862 million. The company's First-Quarter 2024 Operating Results showed revenue growth of 2.3% on a reported basis and 2.9% at constant currency. R&D Solutions revenue increased by 3.4%, Technology & Analytics Solutions revenue grew by 0.6%, and Contract Sales & Medical Solutions revenue rose by 3.8%. The company's contracted backlog reached $30.1 billion, up 7.9% year-over-year. IQVIA reaffirmed its full-year guidance for 2024, expecting revenue growth of 2.3% to 3.9% and Adjusted Diluted EPS growth of 7.4% to 10.3% year-over-year.
FAQ
What is the current stock price of Iqvia Hldgs (IQV)?
What is the market cap of Iqvia Hldgs (IQV)?
